Mount Sinai Researcher Receives Prestigious Award From the American Association of Indian Scientists in Cancer Research
Nina Bhardwaj, MD, PhD, is recognized for lifetime contributions to cancer research and the impact of her work
Nina Bhardwaj, MD, PhD, Director of Immunotherapy at The Tisch Cancer Institute at Mount Sinai, has received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR).
The AAISCR’s Lifetime Achievement award is presented annually to an outstanding scientist who has made significant contributions to cancer research, either through a scientific discovery or through their body of work. These contributions, whether through research, leadership, or mentorship, must have a lasting impact and demonstrate a lifetime commitment to achieving progress against cancer.
Through her research, Dr. Bhardwaj has significantly advanced the understanding of how to fight cancer by using innate immune cells to reverse immunosuppression in tumor microenvironments. In particular, her team discovered a subset of dendritic cells, which play a key role in initiating an immune response. Subsequently she gained further insights on how dendritic cells work by generating and growing them in her lab. Dr. Bhardwaj also developed dendritic-cell-based and dendritic-cell-targeted vaccines for the treatment of both cancer and infection in several investigator-initiated studies and has pioneered neoantigen vaccine studies at The Tisch Cancer Institute.
Prior to receiving this award, Dr. Bhardwaj was named one of Scientific American’s Top 50 researchers, receiving the Award for Medical Research in 2004, and in 2015 she received the Fred W. Alt Award for new discoveries in Immunology from the Cancer Research Institute. Dr. Bhardwaj has served on numerous National Institutes of Health Study Sections and advisory councils and as chair of the Cancer Immunology Steering Committee of the American Association for Cancer Research, where she also serves on the Board of Directors. She has secured multiple federal and foundation grants and has authored more than 200 publications over the course of her career.
“It was a wonderful surprise to receive this award and to join such a prestigious group of previous recipients,” said Dr. Bhardwaj, Medical Director of the Vaccine and Cell Therapy Laboratory, Co-Director of the Cancer Immunology Program, Ward-Coleman Chair in Cancer Research, and Professor of Medicine (Hematology and Medical Oncology), and Urology, at the Icahn School of Medicine at Mount Sinai. “It was also extraordinary to be recognized by such an elite group of peers. When I started in this field, dendritic cells were not considered unique lineages and were thought to be a lesser sibling of monocytes. But with the support of Mount Sinai and, in particular, The Tisch Cancer Institute, we were able to make significant discoveries that helped to expand this field and led to many studies using dendritic cells as cellular vaccine adjuvants. Ultimately, it is exciting to have our efforts validated with this award and it inspires me to continue my work and advance the fight against cancer.”
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.